Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AOC1 | P19801 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517619 | 1.00 | GAA (0.45) | GAAAOC1AOC3CYP17A1CHRNB2 | |
| SCHEMBL629073 | 0.85 | GAA (0.37) | GAACYP17A1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL793757 | 0.83 | AOC1 (0.42) | GAAAOC1AOC3CYP17A1OPRL1 | |
| SCHEMBL29517316 | 0.83 | AOC1 (0.42) | GAAAOC1AOC3CYP17A1OPRL1 | |
| Ammonia Solution, Strong SCHEMBL22749582 | 0.81 | AOC1 (0.41) | GAAAOC1AOC3CYP17A1OPRL1 | |
| Hydrochloric Acid SCHEMBL9953248 | 0.81 | AOC1 (0.44) | GAAAOC1AOC3CYP17A1OPRL1 | |
| SCHEMBL628760 | 0.80 | PDE10A (0.36) | GAAOPRL1 | |
| SCHEMBL31178978 | 0.75 | AXL (0.49) | GAAAOC1AOC3CYP17A1KDM4E | |
| SCHEMBL31178670 | 0.75 | AXL (0.53) | GAAAOC1AOC3CYP17A1KDM4E | |
| SCHEMBL20334567 | 0.74 | CHRNB2 (0.36) | CYP17A1CHRNB2CHRNA4CHRNA7OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3560924-A1 | IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3277681-B1 | IMIDAZOLONYLQUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| CN-106831556-A | Sulfamide compound and preparation method thereof and the purposes as lithate transporter inhibitors class medicine | 成都海创药业有限公司 | 2017-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | GAA 3849/4885AOC1 4417/4885AOC3 3157/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2063/4885AOC1 2518/4885AOC3 4514/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GAA 1987/4885AOC1 1819/4885AOC3 4385/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2122/4885AOC1 2607/4885AOC3 4589/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GAA 2321/4885AOC1 2582/4885AOC3 4555/4885 |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | GAA 2095/4885AOC1 3940/4885AOC3 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.